John Lovecchio, MD

Investigator, Center for Oncology & Cell Biology, Feinstein Institute for Medical Research

Chief, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology,
North Shore University Hospital, Northwell Health

Professor, Obstetrics & Gynecology, Hofstra Northwell School of Medicine

Phone: (516) 562-4438
E-mail: jlovecch@northwell.edu

About the Investigator

John Lovecchio, MD, Chief of Gynecologic Oncology at Northwell Health and Professor of Obstetrics and Gynecology at Hofstra Northwell School of Medicine, is one of the nation’s top clinicians and researchers in the field of uterine and ovarian cancers.

Dr. Lovecchio holds administrative and leadership positions in numerous regional and national organizations and has published extensively. He earned his B.S. degree magna cum laude from the University of Massachusetts and has a Master’s degree in nuclear physics from New York University. After completing his medical degree with honors from the State University of New York at Buffalo, he then completed his residency in Obstetrics and Gynecology at the University Hospitals of Case Western Reserve University and fellowship in Gynecologic Oncology at the University of Miami School of Medicine.

Recently, Dr. Lovecchio was featured in a PBS television documentary titled, “The Whisper: The Silent Crisis of Ovarian Cancer.”

Research Focus

Dr. Lovecchio  is the lead investigator in a collaboration between Northwell Health and the Feinstein Institute for Medical Research to advance the development of a blood test for the early detection of ovarian cancer. The team has been studying the presence and levels of biomarkers such as microRNAs (miRNAs) in diseases. MiRNAs are small (19-25nt), noncoding RNAs that regulate gene expression post-transcriptionally by binding in the 3’ untranslated region (3’UTR) of their specific messenger RNAs and interfering with translation. They are involved in normal cellular development, differentiation and proliferation. However, dysregulation of miRNA expression can have a causal role in malignancies. The presence and expression levels of specific tissue miRNAs have been associated with different types of cancer and clinical outcome. MiRNAs are remarkably stable and are well preserved in formalin fixed, paraffin embedded tissue samples and have been detected in plasma and serum samples, making them ideal candidates for non-invasive biomarkers of disease.

Education

University Of Massachusetts, Boston, Massachusetts
Degree: BS – magna cum laude
1970
Field of Study: Biology

Long Island University, Brookville, New York
Degree: MS – summa cum laude
1971
Field of Study: Radiation Biology

State University of New York at Buffalo – Buffalo, New York
Degree: MD
1975

Case Western Reserve University, Cleveland, OH
Degree: Residency
1979
Field of Study: Obstetrics and Gynecology

University of Miami, Miami, FL
Degree: Fellowship
1982
Field of Study: Gynecologic Oncology

Appointments

2010-Present Professor of Clinical, Obstetrics and Gynecology, Hofstra Northwell School of Medicine
1996-2010 Professor of Clinical, Obstetrics and Gynecology, New York University School of Medicine
1994-1996 Professor of Clinical, Obstetrics and Gynecology, Cornell University Medical College
1988-1994 Associate Professor of Clinical Obstetrics and Gynecology, Cornell University Medical College
1982-1988 Assistant Professor of Clinical Obstetrics and Gynecology, Cornell University Medical College

Honors and Awards

1975 Clyde L. Randall Award for Academic Excellence in Obstetrics and Gynecology

1975, 1979 First Prize – Best research paper written by a resident in Obstetrics and Gynecology, Executive Chief Resident, University Hospitals of Cleveland, Department of Reproductive Biology, Case Western Reserve University, Cleveland, Ohio

1987 President’s Award for best poster presentation, “Five Year Survival of Patients With Peri-Aortic Nodal Metastases in Clinical Stage IB and IIA Cervical Carcinoma”, Society of Gynecologic Oncologists, Miami, Florida, February

2009 American Cancer Society – “Courage and Hope” Award for Clinical and Research Excellence

Publications
  1. Navarro, M.D., Tan, M.A L., Lovecchio, J.L., Hajdu, S.I.: “Case Report: Malignant Struma Ovarii.” Annals of Clin & Lab Sci 34:1, 2004.
  2. Tew, W.P., Tian, C., Chi, D., Menzin, A., Lovecchio, J. L., Bookman, M. A., Lichtman, S. M.: “Treatment outcomes for Older Women with Advanced Ovarian Cancer: Results from a phase III clinical trial (GOG 182).” Crit Rev Oncol Hematol 2009; 72 (Suppl. 1): S17 (abstract)
  3. Tew, W.P., Java, J., Chi, D., Menzin, A., Lovecchio, J. L., Bookman, M. A., Lichtman, S. M.: “Treatment outcomes for Older Women with Advanced Ovarian Cancer: Results from a phase III clinical trial (GOG 182).” ASCO (Abstract) 28; (15s), 5030, 2010
  4. Cohen, S., Shapira, I., Gralla, R., Lovecchio, J., et al.: “Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Mutations in Patients Diagnosed with Ovarian Cancer in a Community Setting: Is it Time to Add Ovarian Cancer to the Amsterdam Criteria for Clinical Diagnosis of HNPCC?” American Society of Human Genetics Abstract 490, p. 168, 2010
  5. Shapira, I., Gralla, R., Weiselberg, L., John, V., Menzin, A., Lovecchio, J., D’Olimpio, J., et. al.: “Utilization and referral for genetic services by 455 unaffected individuals at risk for inherited predisposition to cancer: Pathways to improve identification of individuals at risk for hereditary cancer syndromes.” American Society of Human Genetics Abstract 225, p. 169, 2010
  6. Shapira, I., Gralla, R., Akerman, M., Weiselberg, L., John, V., Lovecchio, J., et. al.: “Does maternal or paternal inheritance of BRCA mutations affect the age of cancer diagnosis?” Journal of Clinical Oncology 29: 337-40, 2011
  7. Shapira, I., Lee, A., Keogh, M., Mason, C., Oswald, M., Lovecchio, J., et. al.: “Circulating microRNA patterns in ovarian cancer, increased expression with surgical intervention and chemotherapy: Stable presurgical survival pattern (SP) microRNA expression may reflect intrinsic ability for recognition and elimination of malignancy.” Proceedings of American Association of Cancer Research 53: p. 1006-10, 2012
  8. Shapira, I., Lee, A., Oswald, M., Lovecchio, J., Menzin, A., Whyte, J., et. al.: “Chemotherapy response in ovarian cancer is modulated by the DNA encoded microRNA family miR-17-92a.” American Society for Human Genetics Abstract 117, p. 87, 2012
  9. Lovecchio, J., Shapira, I., Lee, A., Oswald, M., Gregersen, P., Menzin, A., et. al.: “Plasma micro-RNA pattern, a reliable biomarker able to differentiate epithelial ovarian cancer (EOC) from benign pelvic mass.” International Journal of Gynecologic Cancer, Abstract 323, p. 87, 2012
  10. Fiorica, J., Dalton, H., Monk, B., Lovecchio, J. et. al: “In vitro chemoresponse in metachronous pairs of gynecologic cancers.” British Gynecologic Cancer Society Abstract P133, 2012

View more at PubMed